Showing results (31-40 of 43) with videos related to
Sort By:
Pageof 5
The Journal of Allergy and Clinical Immunology|March 16, 2012
A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitisWarner Carr, Jonathan Bernstein, Phil Lieberman, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 15, 2006
Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working GroupPhil Lieberman, Carlos A Camargo, Kari Bohlke, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 10, 2006
Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and ImmunologyLeonard Bielory, Michael Blaiss, Stanley M Fineman, et al.Allergy and Asthma Proceedings|November 7, 2012
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitisWarner W Carr, Paul Ratner, Ullrich Munzel, et al.The World Allergy Organization Journal|November 16, 2013
Consensus Definition of Nonallergic Rhinopathy, Previously Referred to as Vasomotor Rhinitis, Nonallergic Rhinitis, and/or Idiopathic RhinitisMichael A Kaliner, James N Baraniuk, Michael Benninger, et al.The World Allergy Organization Journal|November 16, 2013
Consensus Description of Inclusion and Exclusion Criteria for Clinical Studies of Nonallergic Rhinopathy (NAR), Previously Referred to as Vasomotor Rhinitis (VMR), Nonallergic Rhinitis, and/or Idiopathic RhinitisMichael A Kaliner, James N Baraniuk, Michael S Benninger, et al.Expert Review of Clinical Immunology|September 2, 2015
Current controversies and challenges in allergic rhinitis managementDavid Price, Pete Smith, Peter Hellings, et al.Expert Opinion on Pharmacotherapy|March 10, 2015
Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gapsJean Bousquet, Claus Bachert, Jonathan Bernstein, et al.International Archives of Allergy and Immunology|May 9, 2013
Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysisEli Meltzer, Paul Ratner, Claus Bachert, et al.The World Allergy Organization Journal|June 13, 2014
International consensus on (ICON) anaphylaxisF Estelle R Simons, Ledit Rf Ardusso, M Beatrice Bilò, et al.Pageof 5